更新后的结果显示,III期NSCLC患者同步放化疗后继续durvalumab巩固治疗具有显著且持久的生存获益。接受durvalumab巩固治疗的患者42.9%在5年时仍然存活,有33.1% 的患者在5年时仍然存活且无疾病进展,本研究为这类患者的标准治疗建立了新的基准。...
更新后的结果显示,III期NSCLC患者同步放化疗后继续durvalumab巩固治疗具有显著且持久的生存获益。接受durvalumab巩固治疗的患者42.9%在5年时仍然存活,有33.1% 的患者在5年时仍然存活且无疾病进展,本研究为这类患者的标准治疗建立了新的基准。 参考文献: 1. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami ...
更新后的结果显示,III期NSCLC患者同步放化疗后继续durvalumab巩固治疗具有显著且持久的生存获益。接受durvalumab巩固治疗的患者42.9%在5年时仍然存活,有33.1% 的患者在5年时仍然存活且无疾病进展,本研究为这类患者的标准治疗建立了新的基准。 参考文献: 1. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami ...
1. S.J. Antonia, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC, N. Engl. J. Med. 379 (2018) 2342–2350. https://doi.org/10.1056/NEJMoa1809697. 2. D.R. Spigel, et al. Five-Year Surviva...
对于不可切除的局部晚期非小细胞肺癌(NSCLC)患者,PACIFIC试验使同步放化疗然后进行度伐利尤单抗(durvalumab)巩固治疗成为标准治疗,添加度伐利尤单抗使5年总生存(OS)率达43%(安慰剂组为33%)[1,2]。 不幸的是,即使加用度伐利尤单抗,大多数患者仍会出现疾病复发。了解后续治疗失败模式(POF)至关重要,因为POF数据通常...
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial.October 2019 Journal of Thoracic Oncology 15(2)DOI: 10.1016/j.jtho.2019.10.002. 绘真医学坐落于美丽的金鸡湖畔,处于被称为中国“生物硅谷”的中国-新加坡合作苏州工业园区中心,依托国外顶尖学府...
1.Spigel D R,Faivre-Finn C, Gray J E, et al. Five-year survival outcomes with durvalumabafter chemoradiotherapy in unresectable stage III NSCLC: An update from thePACIFIC trial[J]. 2021. 2.C. Faivre-Finn presented at European Society for Medical Oncology (ESMO) Virtual Congress 2020, LBA...
1.Spigel D R,Faivre-Finn C, Gray J E, et al. Five-year survival outcomes with durvalumabafter chemoradiotherapy in unresectable stage III NSCLC: An update from thePACIFIC trial[J]. 2021. 2.C. Faivre-Finn presented at European Society for Medical Oncology (ESMO) Virtual Congress 2020, LBA...
参考资料:LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial;2020 欧洲肿瘤内科学会(ESMO)迷你口头报告
[2] N Engl J Med 2017; 377:1919-1929 [4] Spigel D R, Faivre-Finn C, Gray J E, et al. Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial[J]. 2021....